JY
OVID icon

Jeff Yass’s Ovid Therapeutics OVID Stock Holding History

Jeff Yass’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Sell
70,600
-1,876,994
-96% -$4.84M ﹤0.01% 12009
2026
Q1 		$4.32M Buy
1,947,594
+1,605,854
+470% +$2.87M ﹤0.01% 4506
2025
Q4 		$557K Sell
341,740
-247,354
-42% -$381K ﹤0.01% 8521
2025
Q3 		$766K Buy
589,094
+358,849
+156% +$311K ﹤0.01% 7978
2025
Q2 		$76K Buy
230,245
+147,161
+177% +$44.3K ﹤0.01% 11936
2025
Q1 		$25.9K Buy
83,084
+37,964
+84% +$23.3K ﹤0.01% 12052
2024
Q4 		$42.1K Buy
+45,120
New +$50.5K ﹤0.01% 11746
2024
Q1 		– Sell
-22,220
Closed -$71.5K – 13020
2023
Q4 		$71.5K Buy
+22,220
New +$76K ﹤0.01% 11538
2023
Q3 		– Sell
-16,958
Closed -$55.6K – 12703
2023
Q2 		$55.6K Sell
16,958
-146,808
-90% -$499K ﹤0.01% 11295
2023
Q1 		$423K Buy
163,766
+151,717
+1,259% +$360K ﹤0.01% 8980
2022
Q4 		$22.4K Buy
+12,049
New +$20.5K ﹤0.01% 11729
2022
Q2 		– Sell
-307,874
Closed -$744K – 13652
2022
Q1 		$967K Buy
307,874
+21,504
+8% +$67.6K ﹤0.01% 7210
2021
Q4 		$919K Buy
286,370
+89,105
+45% +$305K ﹤0.01% 7525
2021
Q3 		$663K Buy
197,265
+90,545
+85% +$330K ﹤0.01% 8654
2021
Q2 		$417K Sell
106,720
-79,883
-43% -$315K ﹤0.01% 10021
2021
Q1 		$750K Buy
186,603
+23,444
+14% +$77.9K ﹤0.01% 8465
2020
Q4 		$377K Buy
163,159
+133,279
+446% +$621K ﹤0.01% 8843
2020
Q3 		$172K Sell
29,880
-40,403
-57% -$270K ﹤0.01% 9592
2020
Q2 		$518K Sell
70,283
-235,419
-77% -$1.1M ﹤0.01% 7292
2020
Q1 		$911K Buy
305,702
+189,367
+163% +$638K ﹤0.01% 5622
2019
Q4 		$483K Buy
+116,335
New +$367K ﹤0.01% 7052

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jeff Yass's OVID Position: Q2 2026 in Review

Jeff Yass reduced its Ovid Therapeutics (OVID) stake by 96% in Q2 2026, selling an estimated $4.84M and leaving 70,600 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #12009.

Jeff Yass first reported a position in OVID in Q4 2019 and has held it in 21 quarters since. The position peaked at $4.32M in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Jeff Yass held 70,600 shares of Ovid Therapeutics worth $190K as of Q2 2026.
  • Jeff Yass sold 1,876,994 Ovid Therapeutics shares in Q2 2026, an estimated $4.84M.
  • Ovid Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12009 holding.
  • Jeff Yass first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Ovid Therapeutics position peaked at $4.32M in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.